(6R)-6-acetyl-6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (6R)-6-acetyl-6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one
• 化学式: C₁₁H₁₇N₃O₆
• 分子量: 287.27
• InChiKey: BCZUPRDAAVVBSO-UEWQFTGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  145
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• [EN] NUCLEIC ACID POLYMERS<br/>[FR] POLYMÈRES D'ACIDES NUCLÉIQUES
  申请人：JANSSEN BIOPHARMA INC

  公开号：WO2021198958A1

  公开（公告）日：2021-10-07

  A nucleic acid polymer comprising 8 to 50 nucleoside subunits linked by intersubunit linkages, wherein the nucleic acid polymer comprises (A) one or more 3'-5' thiophosphoramidate intersubunit linkage and the remaining intersubunit linkages are 3'-5' thiophosphate intersubunit linkages and/or (B) at least 40% of the nucleoside subunits contain a 2'-MOE substituent. Those nucleic acid polymers are useful in the treatment of a viral infection, more specifically Hepatitis B virus and/or Hepatitis D virus.

  一种包含由互补亚单位连接的8至50个核苷酸亚单位的核酸聚合物，其中该核酸聚合物包括（A）一个或多个3'-5'硫代磷酰胺亚单位连接，其余的亚单位连接为3'-5'硫酸酯亚单位连接和/或（B）至少40%的核苷酸亚单位含有2'-MOE取代基。这些核酸聚合物在治疗病毒感染中有用，更具体地是乙型肝炎病毒和/或丙型肝炎病毒。
• MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES
  申请人：Janssen Pharmaceutica NV

  公开号：EP3765476A2

  公开（公告）日：2021-01-20
• STRUCTURALLY DEFINED SIRNA-DUAL VARIABLE DOMAIN IMMUNOGLOBULIN CONJUGATES
  申请人：Alnylam Pharmaceuticals Inc.

  公开号：EP3986475A1

  公开（公告）日：2022-04-27
• [EN] MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE IN TAUOPATHIES<br/>[FR] OLIGONUCLÉOTIDES MODIFIÉS ET MÉTHODES D'UTILISATION DANS LES TAUOPATHIES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019175260A2

  公开（公告）日：2019-09-19

  Oligonucleotides comprising modifications at the 2' and/or 3' positions(s) along with methods of 5 making and use against Alzheimer disease and other tauopathies are disclosed.
• [EN] STRUCTURALLY DEFINED SIRNA-DUAL VARIABLE DOMAIN IMMUNOGLOBULIN CONJUGATES<br/>[FR] CONJUGUÉS D'IMMUNOGLOBULINE À DOMAINE VARIABLE DOUBLE D'ARNSI STRUCTURALEMENT DÉFINI
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2020257483A1

  公开（公告）日：2020-12-24

  The disclosure is directed to dual variable domain immunoglobulin double-stranded RNA conjugates that are advantageous for inhibition of target gene expression, as well as compositions suitable for therapeutic use. The dual variable domain immunoglobulin comprises a first variable domain that binds to a binding target, and a second variable domain that comprises a reactive residue, where the linker is covalently conjugated to the reactive residue. The dsRNA is linked to the linker and is capable of inhibiting the expression of the target gene by RNA interference. The disclosure also provides pharmaceutical compositions comprising these conjugate and methods of inhibiting the expression of a target gene by administering these conjugates, e.g., for the treatment of various disease conditions.